Abbott Laboratories (ABT)

Health care companies will likely continue their battle over a soured merger in Delaware court.

- FREESTYLE LIBRE PRO IS A CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM DESIGNED TO PROVIDE A CLEAR, VISUAL SNAPSHOT OF A PATIENT'S GLUCOSE LEVELS, TRENDS AND PATTERNS FOR UP TO 14 DAYS

The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

- NEW RESEARCH SHOWS THAT MALNUTRITION ASSOCIATED WITH DISEASE INCREASES MEDICAL SPENDING BY MORE THAN $1 BILLION YEARLY IN CALIFORNIA, NEW YORK, TEXAS AND FLORIDA[1]

MYOPLEX® KETOGENIC DELIVERS THE RIGHT AMOUNT OF NUTRIENTS NEEDED TO SUPPORT A KETOGENIC REGIMEN AND HELP ATHLETES ACHIEVE THEIR BODY AND PERFORMANCE GOALS

The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.

U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.

Abbott Laboratories (ABT) will sell its eye surgery unit to Johnson & Johnson (JNJ) for $4.325 billion in cash.

- Abbott continues to shape its portfolio for long-term growth

Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?

These sectors are full of high-priced, low-growth stocks.

Cramer is sticking with International Paper and likes Advanced Micro Devices.

This is not the time to sell in a panic, Cramer says.

Abbott Labs shares have been all over the place in the last year as the company makes deals. Investors are wondering if they should hold on.

Abbott Laboratories (ABT) and Alere (ALR) agreed today to work with a mediator to solve issues in their ongoing merger dispute.

- Achieves top industry scores in all three categories of economic, environmental and social performance, and more than doubles the overall average industry score

The cardiac device maker has filed a lawsuit against the Muddy Waters, claiming the short-seller intentionally disseminated false and misleading information.

Zoetis' valuation doesn't reflect opportunities from innovation, operational improvements, and capital allocation, according to one analyst.

Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.

Alere claims that Abbott is slow-rolling the antitrust process on the companies' merger in an effort to kill the deal.

The leadership is quite stark.

The provider of point-of-care testing has filed a suit in Delaware Chancery Court against Abbott in an effort to complete their pending deal. Meanwhile, St. Jude, gets a griping short-seller.

Alere (ALR) sued Abbott (ABT) on Friday saying the medical device company failed to get U.S. antitrust approval for its merger.

Abbott Laboratories (ABT) stock was increasing Thursday afternoon as Muddy Waters attempts to break up the company's proposed acquisition of St. Jude (STJ).

Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.